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INTRODUCTION 
Carcinoma Breast is a complex heterogenous disease and is the most 
common cancer in women globally ,based on different cancer registries data, 
accounting for approximately 1.4 million cases each year, with more than half 
of the 400,000 deaths caused by carcinoma Breast occurring in lower -middle 
income Countries. It has surpassed Carcinoma Cervix to become the leading 
cause of Cancer-related mortality among women living in a developing 
country like India, having placed incidence of the disease at 30 to 33 per 1, 
00,000 women in urban India.  
The number of cases of Carcinoma Breast in India is about 100,000 
women each year and the count will be approximately 2, 50,000 new cases of 
breast cancer in India in upcoming decade. The Incidence of Carcinoma 
Breast has doubled in India over the last few decades.  
The increasing incidence could be attributed to the increasing working 
women population which may increase the probability of exposure to various 
risk factors. 
Data at BIR & O  shows that about  20 %-25% of all cancers registered 
are female carcinoma breast, the incidence of male Carcinoma Breast is about 
1%. 
The standard of care for  Carcinoma Breast is multi modality which is 
surgery (either breast conservation surgery  or modified radical mastectomy ) 
either neoadjuvant or adjuvant chemotherapy depending on the stage at 
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diagnosis followed by Radiotherapy as indicated since there is a higher 
incidence of local recurrence followed by Hormonal therapy depending on the 
receptor status and menstrual status.  
Majority of the cases presented in BIR & O have either neoadjuvant 
chemotherapy followed by Modified radical mastectomy followed by adjuvant 
chemotherapy and referred to our Department for feasibility of post 
mastectomy radiotherapy, whereas a small percentage usually less than 20% 
are prescribed palliative Radiotherapy to chest wall and whole breast 
irradiation. 
Many studies have confirmed the rationale for post mastectomy 
radiation which is the prevention of a local-Regional recurrence.The 
theoretical idea is that clinically occult persistent disease maybe present in 
the operative site and draining nodes which may act as a source of metastases, 
thus targeting operative site through radiotherapy which may have a 
beneficial effect on the patients. 
The conventional radiotherapy dose is 200CGy delivered  over 25 
fractions for a total dose of 50Gy for a duration of 5 weeks including the 
posterior axillary boost so which accounts for a duration of 70 days minimum 
since it includes the time for chemotherapy and surgery and clinical analysis 
which causes a loss in Disability adjusted life years and physical ,emotional 
burden and social isolation both for the patient and the family.Thus in turn the 
hospital setup and staff undergoes extra work which puts up a challenge for 
the hospital invariably causing huge amount of work pressure on every 
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worker especially the supporting workforce( physicians and physicist and the 
radiographers).  
Many top centres around the world nowadays practice a sound 
established, hypofractionated protocol for pmrt which reduces the total 
number of fractions and in turn the treatment duration.When it comes to the 
protocol prescription dose which is  4000 CGy delivered over 15 fractions 
with 2.67Gy per fraction is being practiced and has been considered as a fair 
standard dosage world over after stringent trials.  
The hypofractionation in cancer treatment has been studied extensively 
and is considered a routine in many parts of the world to use this approach in 
palliative care. Different schedules have been developed to minimize the 
burden on machines and operators. The data obtained has induced interest 
about hypofractionation in curative setting and its possible reduction on the 
load to all concerned.The protocols tried have been recorded to show good 
local control, equivalent toxicities and cosmetic outcome.  
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LITERATURE REVIEW  
EPIDEMIOLOGY 
Ca Breast is the most challenging disease because it is the most 
frequently diagnosed cancer and  presents  in multiple ways, and it is the 
leading cause of cancer death in female‟s worldwide accounting for 23% 
of the total new cancer cases and 14% of the total cancer deaths. 
Economically insufficient countries account for about half the Ca Breast 
cases and over 60% of the deaths occur in these regions.  incidence rates 
are high in Western and Northern Europe, Australia/New Zealand, and 
North America; intermediate in South America, the Caribbean, and 
Northern Africa; and low in Sub-Saharan Africa and Asia.  
Geographical spread of the disease is complex with the highest 
incidences seen in the more developed regions of the world and the 
lowest incidences observed in the least developed regions .according to 
SEER data  which says that around 1 in 8 U.S. women  will develop 
invasive Ca Breast over her entire lifetime.  
The factors that contribute to the international variation in 
incidence rates largely arise from differences in reproductive and 
hormonal factors which are causative factors and the availability of 
early detection services  which are diagnostic services.  
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In 2015, an 242,476 new cases of invasive Ca Breast were 
diagnosed in women in the U.S., A man‟s lifetime risk of Ca Breast is 
about 1 in 1,000. 
Table 1:Surveillance, Epidemiology and end Results registry 
Year 
New Cases -  
SEER 9 
New Cases -  
SEER 13 
Deaths - U.S. 
Percent Surviving 
5 Years - SEER 9 
Observed 
Modeled 
Trend 
Observed 
Modeled 
Trend 
Observed 
Modeled 
Trend 
Observed 
Modeled 
Trend 
1975 105.08 103.34 - - 31.45 31.48 75.31% 74.47% 
1976 101.94 102.77 - - 31.8 31.59 74.51% 74.68% 
1977 100.79 102.21 - - 32.48 31.7 75.02% 74.89% 
1978 100.6 101.65 - - 31.73 31.82 74.47% 75.10% 
1979 102.08 101.1 - - 31.21 31.93 74.16% 75.31% 
1980 102.23 100.54 - - 31.68 32.04 74.96% 75.51% 
1981 106.35 104.54 - - 31.92 32.16 75.65% 75.72% 
1982 106.5 108.69 - - 32.19 32.27 76.49% 75.92% 
1983 111.11 113.01 - - 32.07 32.38 76.43% 76.12% 
1984 115.99 117.5 - - 32.9 32.5 78.25% 77.89% 
1985 124.26 122.17 - - 32.98 32.61 78.53% 79.55% 
1986 126.84 127.02 - - 32.87 32.73 80.23% 81.10% 
1987 134.52 132.07 - - 32.66 32.85 83.30% 82.55% 
1988 131.39 131.85 - - 33.2 32.96 84.58% 83.90% 
1989 127.3 131.63 - - 33.23 33.08 84.40% 84.42% 
1990 131.92 131.41 - - 33.14 33.2 84.68% 84.92% 
1991 133.87 131.19 - - 32.69 32.62 85.26% 85.41% 
1992 132.1 130.97 129.97 126.85 31.64 32.04 85.84% 85.89% 
1993 129.23 130.75 127.23 128.55 31.39 31.48 85.76% 86.35% 
1994 131.01 130.53 128.79 130.27 30.92 30.93 86.59% 86.79% 
1995 132.71 132.85 130.94 132.02 30.55 30.39 86.84% 87.23% 
1996 133.8 135.21 132.17 133.79 29.49 29.36 86.73% 87.65% 
 8 
Year 
New Cases -  
SEER 9 
New Cases -  
SEER 13 
Deaths - U.S. 
Percent Surviving 
5 Years - SEER 9 
Observed 
Modeled 
Trend 
Observed 
Modeled 
Trend 
Observed 
Modeled 
Trend 
Observed 
Modeled 
Trend 
1997 138.1 137.62 136.15 135.58 28.21 28.36 88.43% 88.06% 
1998 141.49 140.07 139.07 137.4 27.54 27.4 89.55% 88.45% 
1999 141.52 142.56 138.59 139.24 26.61 26.9 89.64% 88.83% 
2000 136.62 139.3 134.29 136.17 26.64 26.41 90.25% 89.20% 
2001 138.86 136.12 135.9 133.17 26.01 25.93 89.55% 89.56% 
2002 135.89 133.01 132.9 130.24 25.62 25.46 90.31% 89.91% 
2003 127.13 129.97 124.29 127.37 25.27 25 89.86% 90.25% 
2004 128.26 127 125 124.56 24.49 24.55 90.04% 90.57% 
2005 126.72 127.4 124.53 124.81 24.14 24.1 90.65% 90.89% 
2006 126.44 127.79 122.96 125.06 23.56 23.66 90.87% 91.20% 
2007 128.33 128.19 126.2 125.3 22.96 23.23 91.26% 91.13% 
2008 128.53 128.59 126.38 125.55 22.55 22.81 90.76% 91.06% 
2009 130.97 128.99 127.89 125.8 22.24 22.4 91.39% 90.98% 
2010 127.07 129.39 123.7 126.05 21.92 21.99 90.90% 90.91% 
2011 130.46 129.79 127.16 126.3 21.54 21.59 - 90.84% 
2012 130.15 130.19 126.72 126.55 21.27 21.2 - 90.77% 
2013 131.03 130.6 127.1 126.8 20.74 20.81 - 90.70% 
2014 131.19 131 126.08 127.05 20.55 20.43 - 90.62% 
2015 131.1 131.41 127.45 127.3 20.31 20.06 - 90.55% 
But  the surprsing news is from 1999 to 2005, Ca Breast incidence 
rates in the U.S. decreased by about 2% per year. The decrease was seen 
only in women aged 50 and older. The theoretical statement is that this 
decrease was partially due to the reduced use of hormone Replacement 
therapy (HRT) by women after the results of a large study called the 
Women‟s Health Initiative.  
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These results suggested a connection between HRT and increased 
Ca Breast risk and which led to scientific discussions. though death rates 
have been decreasing since 1990 – especially in women under 50 years 
of age 
These decreases are thought to be the result of treatment 
advances, earlier detection through screening, and increased awareness. 
In 2011, there were more than 2.6 million Ca Breast survivors in the US. 
But when it comes to India The number of women estimated to be dying 
of Ca Breast every year has been steadily mounting and raising concerns 
among the healthcare fraternity. Data records tells us that around 48,170 
women who died of Ca Breast in 2007, this slowly increased and 
reached the 50,000 mark in 2010; now at present it is 87090 ,with a 
ranking of number 1. 
India has a rich mix of culture practices,tradition which has led to 
a period of complex social and economic change. Cancer is now the 
second leading cause of death in Indians after cardiovascular disease, 
Women diagnosed with Ca Breast in India are on average 10 years 
younger than the Western countries.  
In India, a majority of the Carcinoma Breast cases present as late 
advanced stages. "The lifetime probability of developing Ca Breast in 
India is one in 22 women compared to one in eight in US and other 
 10 
developed countries. In India, the number of new Ca Breast cases is 
162,468 cases per year and this is expected to rise and surpass others.  
The age standardised mortality rate for Ca Breast in India is 19 
per 100000 (24.7per 100000 globally). In common with other 
developing regions mortality rates for Ca Breast in India are high in 
comparison to incidence rates. This explains the poor survival rate 
which is attributed to the lack of access or limited access to early 
detection and treatment. 
 
Table 2: Statistics of Breast Cancer cases in India 
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Table 3:Statistics of cancer cases in India 
 
Table 4 :Breast Cancer cases in India:Statistics : GLOBOCAN 2018  
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Figure 1:Geographical depiction of incidence of cancer cases in India  
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I. RISK FACTORS AND CAUSES 
Both in the developing and developed nations,Carcinoma Breast 
accounts for higher incidence rates because of the many risk factors and 
causative factors.  
1) Gender: Woman is the main risk for Ca Breast. While men 
occasionally get the disease; it is many times more common in 
women than in men. 
2) Age: Older women have a higher chance of getting Carcinoma 
Breast and about two-third of the  women with invasive Ca Breast 
are 55 or older when the cancer is detected 
3) Genetic mutations: About 5% to 10% of Ca Breasts are due to 
gene mutations. The most common gene mutations are those of 
the BRCA1 and BRCA2 genes Women with these gene changes 
Have up to an 80% chance of getting breast cancer during their 
lifetimes. 
4) Race: Overall,white women are slightly more prone to get Ca 
Breast than African-American women. But in less than 45 years of 
age ,African American women,  
5) Family history: Breast cancer risk is higher among women whose 
close blood relatives have this disease. Having a mother, sister 
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with breast cancer the risk is 1.7 to 2.5 and aunt or grandmother 
with breast cancer ,the risk is 1.5 
6) Personal history of breast cancer: A woman with cancer in one 
breast has a greater chance of getting contralateral breast cancer 
or in another quadrant. 
7) Menstrual history: Women who attained menarche early (before 
age 12) or who attain menopause after the age of 55 have a 
slightly increased risk of breast malignancy.  
8) Dense breast tissue: Dense breast tissue means there is more 
gland tissue and less fatty tissue .Thus Women with denser breast 
tissue have a higher risk of Ca Breast 
9) Lobular carcinoma in situ: Women with lobular carcinoma in 
situ (LCIS) have a 7 to 11 time‟s greater risk of developing cancer 
in either breast. 
10) Nulliparous women or Not having children or delayed child 
birth: Women who have no children, or who had their first child 
after age 30, have a slightly higher risk of Ca Breast  
11) Alcohol: The use of alcohol is clearly linked to an increased risk 
of getting Ca Breast. Those who have 60ml to 150ml drinks daily 
have about 1½ times the risk of women who drink no alcohol 
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12) Body Mass Index: Based on BMI overweight or obese is linked 
to a higher risk of Ca Breast, especially for women after 
menopause or if the weight gain took place during adulthood.  
13) Breast radiation early in life: Women who have had radiation 
treatment to the chest area (as treatment for other conditions like 
hodgkins lymphoma and diagnostic fluoroscopy) earlier in their 
lifehood have a greatly increased risk of Ca Breast. The risk from 
chest radiation is highest if the radiation were given during the 
adolescence period,because this gives a latent period of 10- 15 
years that is  when the breasts were still developing.Radiation 
treatment after age 40 does not seem to increase Ca Breast risk.  
14) Treatment with Diethylstilbestrol: In the past, some pregnant 
women were given this drug.Studies have shown that these 
women and the children exposed in the womb have a slightly 
increased risk of getting Carcinoma Breast.  
15) Recent use of birth control pills: Studies have found that women 
who are using birth control pills have a slightly greater risk of Ca 
Breast than women who have never used them 
16) Using hormone therapy after menopause: This has been proven 
by many studies and its withdrawal and stoppage of this therapy 
has lead to a decline in the rise of new cases of breast cancer. 
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17) Combined Hormonal therapy: Use of combined Hormonal 
therapy after menopause increases the risk of  getting Ca Breast.It 
may also increase the chances of dying from Ca Breast. Ca Breast 
in women taking hormones may also be found at a more advanced 
stage 
18) Not breast-fed: Some studies have shown that breast-feeding 
slightly lowers Ca Breast risk, especially if the breast -feeding 
lasts 1½ to 2 years.This decreased 4.3% of the relative risk of 
breast cancer for 12 months of breast feeding. 
19) Estrogen Replacement Therapy: some studies have found that 
Estrogen replacement therapy increases the risk of ovarian and Ca 
Breast, if used for more than a decade.  
II. PATHOLOGY 
A. INVASIVE BREAST CANCER 
1) Invasive (Infiltrating) Ductal Carcinoma (IDC) : It is the most 
common type of Ca Breast.3/4ths of the cases of invasive Ca 
Breasts are classified as invasive ductal carcinoma  
2) Invasive (Infiltrating) Lobular Carcinoma: Lobular Carcinoma 
originates from the milk- producing lobules where it extends into 
the surrounding adipose tissue of the breast.It is relatively 
uncommon, comprising about 10% of invasive breast cancers 
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compared with IDC, patients with ILCs often have bilateral 
disease 
3) Tubular Carcinoma is a highly differentiated invasive carcinoma 
and pure tubular carcinoma has limited metastatic potential and 
better than average prognosis.  
4) Medullary Carcinoma is a relatively uncommon type of invasive  
carcinoma, accounting for less than 5% to 7% of all invasive Ca 
Breasts. The prognosis for this type of Ca Breast is quite 
favourable when compared to the other types.  
5) Mucinous Carcinoma, also called colloid carcinoma, is an 
invasive form of Ca Breast characterized by large amounts of 
extracellular mucin production. This histopathological type 
confers a relatively favourable prognosis.  
6) Metaplastic Carcinoma is uncommon, representing less than 5% 
of all Ca Breasts. Prognostic implications of this type of breast 
cancer are unpredictable. 
7) Invasive Cribriform Carcinoma is a well- differentiated cancer  
comprised of Small and uniform cells. It shares some features 
with tubular carcinoma and is also associated with better than 
average prognosis 
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8) Invasive Micropapillary Carcinoma is a distinct but poorly 
recognized variant of breast cancer, usually presenting as a firm,  
Immobile mass. Pure micro papillary carcinoma is uncommon, 
limited research suggests that this type of cancer may be 
associated with a relatively poor prognosis  
9) Invasive Papillary Carcinoma is very rare comprising less than 
1% to 2% of invasive breast cancers and a predominant 
presentation in postmenopausal women , it is characterized by 
nodular densities that may be Multiple and are frequently 
lobulated. Available data suggests relatively favourable prognosis  
 
OTHER BREAST CANCER TYPES 
1) Inflammatory Breast Cancer is a unusual form of locally 
advanced breast cancer. Patients present acute onset of clinical 
features including signs of inflammation, warmth, thickening or 
dimpling ,peau d' orange and a clinically palpable ridge at the 
margin of induration . Inflammatory breast cancer is relatively 
rare, representing about 1% to 5% of all Ca Breasts and has a less 
favourable than Average prognosis 
2) Paget’s Disease of the Nipple presents either in situ or invasive 
cancer;but has an excellent prognosis rate when associated with 
carcinoma in situ, which accounts for  1% of all Ca Breasts.  
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3) Phyllodes Tumors can present as benign, borderline or 
malignant. Rare presentation is malignancy. Phyllodes tumors are 
biphasic and composed of benign epithelial elements and Cellula r 
connective tissue stroma.They can grow to a relatively large size 
within a few months, although rapid growth does not necessarily 
indicate malignancy 
TUMOR BIOLOGY: BREAST CANCER 
Genetic changes that occur in cancer include mutation of key 
regulatory genes, changes in protein products, and changes in the 
amount of product produced by genes (gene expression). As changes 
accumulate, cells become more abnormal and cancer progresses  
Some of the genetic elements that have been shown to be 
important in the development of Ca Breast are listed below:  
1) BRCA1 and BRCA2 Genes-tumour suppressor genes,thus 
germline mutations increases risk of breast cancer by 65%-85% 
2) Estrogen and Progesterone receptor-attributed to increase 
exposure to hormones  
3) HER-2/neu Gene-determines the prognosis and metastasis  
4) TP53 Gene and Li-Fraumeni Syndrome-guardian of the genome 
and lifetime risk of 90%  
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5) PTEN Gene and Cowden Syndrome-autosomal dominant and 
benign and malignant growth.  
6) ATM Gene and Ataxia-Telangiectasia-autosomal recessive and 
features neurological clinical features.  
HORMONE RECEPTOR STATUS IN INDIA 
Desai et al. reported on 798 patients where the median age was 48 
years and found 33% were ER+ and 46% were PR+, Data on combined 
receptor profiles found 25% were ER+/PR+, 
7% were ER+/PR− 
21% were ER−/PR+ and 
47% were ER−PR−. 
Twenty percent of patients were found to be Her-2 positive. 
Table 5 :Comparision of cases based on histopathology 
Author 
No. of 
Patients 
Mean 
Age 
Median 
Size 
Histology Grade 
LN ER PR 
IDC ILC 1 2 3 
Saxena 
etal 
569   88% 4%    80%   
Dinshaw 
et al 
1022 43 30 92% 2% 2% 26% 70% 39% 33% 41% 
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NATURAL COURSE AND CLINICAL FEATURES  
As the cancer grows, it breaches the basement membrane and invades 
the adjacent lobules, ducts and presents as lump in the breast or  discharge 
from nipple with associated with no or mild pain or discomfort.  
The tumour may spreads into deep lymphatics of the dermis and 
produces oedema of the skin called Peau d „orange and a common feature.The 
tumour may involve the skin directly and cause ulceration or Nodules in the 
skin.Posterior extension of the tumor to pectoralis fascia and muscle may 
cause fixity which can be detected by contracting the muscle. More advanced 
cases can cause chest wall invasion i.e. involvement of ribs or intercosta l 
muscle and or serratus anterior produce fixity of the tumour when these 
muscles are at action or at rest.  
T1 and T2 Ca Breast have pathological evidence of axillary nodal 
metastasis which is approximately 10 – 40% of newly diagnosed stage and in 
T3 and T4 disease the percentage is higher. 
Metastasis to the internal mammary nodes is an entity and  is often 
correlated with tumour size, lesions in the inner and central quadrant and 
when the axillary nodes are involved. Supraclavicular nodal involvement is 
common when there is axillary and IMN involvement or when there is direct 
infiltration of skin of upper half of the breast by the tumour.  
Haematogenous spread to the distant sites is very common in cancer 
breast even when the tumour size is small. The commonest sites are lung, 
pleura, bone, brain, adrenal glands and liver.ovaries, etc 
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Molecular profiling has led to classification of Ca Breast into the 
following five distinct subtypes. 
Table 6:Molecular Classification of Breast Cancer subtypes  
Luminal A ER positive,PR positive,HER2 negative 
Luminal B ER positive,PR positive,HER2 positive 
HER 2 LIKE ER negative,PR negative,HER2 positive  
BASAL LIKE ER negative,PR negative,HER2 negative 
Table 7: AJCC Staging of Breast Cancer 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis(DCIS) Ductal carcinoma in situ (DCIS) 
Tis 
(Paget) 
Paget disease of the nipple NOT associated with invasive 
carcinoma and/or carcinoma in situ (DCIS) in the 
underlying breast parenchyma. Carcinomas in the breast 
parenchyma associated with Paget disease are categorized 
based on the size and characteristics of the parenchymal 
disease, although the presence of Paget disease should still 
be noted. 
T1 Tumor ≤ 20 mm in greatest dimension 
T1mi Tumor ≤ 1 mm in greatest dimension 
T1a Tumor > 1 mm but ≤ 5 mm in greatest dimension (round 
any measurement from >1.0‐1.9 mm to 2 mm) 
T1b Tumor > 5 mm but ≤ 10 mm in greatest dimension 
T1c Tumor > 10 mm but ≤ 20 mm in greatest dimension 
T2 Tumor > 20 mm but ≤ 50 mm in greatest dimension 
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T3 Tumor > 50 mm in greatest dimension 
T4 Tumor of any size with direct extension to the chest wall 
and/or to the skin (ulceration or macroscopic nodules); 
invasion of the dermis alone does not qualify as T4 
T4a Extension to the chest wall; invasion or adherence to 
pectoralis muscle in the absence of invasion of chest wall 
structures does not qualify as T4 
T4b Ulceration and/or ipsilateral macroscopic satellite nodules 
and/or edema (including peau d‟orange) of the skin that 
does not meet the criteria for inflammatory carcinoma 
T4c Both T4a and T4b are present 
T4d Inflammatory carcinoma  
 
Table 8:Survival by Presenting Stage of Breast Cancer 
Stage 5 Year survival (%) 
0 100% 
I 98% 
IIA 88% 
IIB 76% 
IIIA 56% 
IIIB, IIIC 49% 
IV 16% 
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Table 9: Incidence of Lymph Node Metastasis in Invasive Breast 
Carcinoma 
Tumour size (cm) <0.5 0.5-1.0 1.1-2.0 2.1-3.0 3.1-5.0 
Incidence (%) 3-7% 12-17% 20-30% 35-45%  40-60% 
WORK UP 
1) Physical examination - loco regional extent of tumour i.e. 
size,ulceration,nodules,peau d orange,dimpling of the skin and 
examination of  potential sites of spread.  
2) Laboratory studies include a complete blood cell count, serum 
bichemistry profile, and liver function tests.  
3) If liver function values are abnormal, a computed tomography 
(CT) scan of the abdomen should be obtained plus skeletal survey 
and bone scan should be done. 
4) If anaemia, leukopenia, or thrombocytopenia is present, bone 
marrow biopsy might be necessary.  
5) Radiographic studies include chest x-ray, bone scans, and plain 
radiographs of symptomatic regions or suspicious areas of 
increased uptake on bone scans .  
6) CT scans of the chest and abdomen are obtained routinely. 
7) Bone scans generally are recommended for stage III or IV disease, 
even when the Alkaline phosphatase level is normal.  
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8) If neurologic symptoms suggest brain metastases, a contrast -
enhanced CT scan or gadolinium-enhanced magnetic resonance 
imaging scan of the brain should be obtained; magnetic resonance 
imaging is preferred if leptomeningeal carcinomatosis is 
suspected . 
TREATMENT OF BREAST CANCER 
Multimodality integrated treatment has been proved  the best 
tumour control and survival for early stages, breast conservative 
treatment includes a combination of the three treatment modalities 
surgery, radiation therapy, and chemotherapy have shown the 
effectiveness required for survival.For advanced stages, the primary 
treatment includes a combination of surgery and chemotherapy, with 
selective use of postmastectomy radiation therapy in certain cases.  
SURGERY 
Lumpectomy is appropriate for DCIS, and stages T1, T2 ,Invasive 
Ductal or lobular Ca Breast. Mastectomy is indicated in all patients who 
are not Suitable for breast conservation. Breast conservation surgery 
(BCS) may consist of (in order of decreasing tissue removed) : 
quadrantectomy, wide excision, lumpectomy (local excision) .  
Indications for surgery 
T3,T4 stage 
Multifocality,Multicentricity 
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CONTRAINDICATIONS FOR SURGERY 
Metastatic disease 
VARIATIONS OF MASTECTOMY 
1) Radical Mastectomy: removal of breast, pectoralis minor and 
major muscles, axillary LN dissection (ALND) (levels I–III) 
2) Modified Radical Mastectomy removal of breast to the level of  
pectoralis minor muscle, ALND (levels I–II) while the spared one 
is  pectoralis major 
3) Total (Simple) Mastectomy  is removal of breast to the level of 
pectoralis minor muscle with no lymph node dissection 
4) Skin Sparing Mastectomy: preserves skin of  the breast for 
enhanced reconstructive cosmetic outcomes 
Total Skin Sparing Mastectomy preserves skin and nipple/ 
areolar complex for enhanced reconstructive outcome for invasive 
cancers, sentinel axillary lymph node sampling with or without 
subsequent Axillary dissection for positive sentinel node is routinely 
completed reconstructive options postmastectomy include delayed vs. 
Immediate, and autologous tissue vs. expander/implant.  
SYSTEMIC THERAPY  
For women younger than 50 years, polychemotherapy reduced the 
annual risk of disease relapse and death from Ca Breast by 37% and 
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30%, respectively. This translated into a 10% absolute improvement in 
15-year survival (HR = 42% vs. 32%). For women aged 50 to 69 years, 
the annual risk of relapse or death from Ca Breast was decreased by 
19% and 12%, respectively. This translated into a 3% absolute gain in 
15-year survival (HR = 50% vs. 47%). The absolute gain in survival for 
polychemotherapy versus no adjuvant therapy in Women younger than 
50 was twice as great at 15 years as it was at 5 years(10% vs. 4.7%), 
while the main effect on disease recurrence was present in the first 5 
years. 
Anthracyclines (doxorubicin)-based regiments (± taxanes for 
high-risk disease) have been associated with superior out comes as 
compared to nonanthracycline containing regimens with recent evidence 
augmenting the increased DFS and OS with taxane-based therapy as 
compared to anthracyclin-based therapy 
Neoadjuvant chemotherapy is considered standard of care in high-
risk populations such as young patients and/or advanced- stage disease, 
and has been evaluated in Stage II– IIIa Ca Breast in large number of 
randomized trials  
Neoadjuvant chemotherapy converts 20–30% of patients initially 
ineligible for BCT to eligible category patients. For advanced-stage 
disease, 20–40% achieve cCR after neo adjuvant chemotherapy  
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HORMONAL THERAPY 
Hormonal therapy has been indicated in almost many patients.It is 
usually with tablet Tamoxifen or Tablet Letrozole and the post 
menopausal women Ca Breasts are more ER / PR positive, they respond 
well with hormonal therapy in the form of loco regional control and 
disease progression.In case of pre menopausal women hormonal therapy 
is indicated only if there is positive ER / PR status.  
RATIONALE FOR USING POST MASTECTOMY 
RADIATION THERAPY 
Virtually every Post Mastectomy Radiation Therapy randomized 
trial to date has demonstrated a reduction in the risk of loco regional 
recurrence with the use of comprehensive Radiotherapy.Prevention of 
Loco regional failure is an important part in oncology management and 
loco regional recurrences can be subsequently controlled by Post 
Mastectomy Radiation Therapy to improve survival.Radiotherapy must 
be able to sterilize residual loco regional disease which, if left untreated, 
could lead to disease progression.The patients who would potentially 
benefit are those without micro metastatic disease at presentation or 
patients with micro metastatic disease effectively treated by systemic 
therapy. Randomized trials have shown inconsistent reduction in the 
rates of Loco Regional Failure with systemic therapies alone and the 
need for adjuvant therapy in the form of radiation is necessary.  
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RADIOTHERAPY TREATMENT TECHNIQUES 
Early Breast Cancer Trialists‟ Collaborative Group published 
many meta-analysis which shows that usually the post mastectomy 
irradiation of the chest wall is done in all T3, T4 disease, and positive 
margin and in case of > 4 nodes positive for tumor. The Principle behind  
is to sterilize the micro metastasis presents locally and regionally.  
The technique of the treatment is patients positioned usually in 
supine position with ipsilateral arm abducted to 90º at shoulder level and 
the elbow flexed at 90º and the head is turned towards opposite side. 
The treatment consists of two parts , flap and drainage field. The target 
volume of the Chest wall field includes chest wall with a small portion 
of underlying lung in the Irradiated volume .When it is combined with a 
supraclavicular portal, the upper margin of the portal is placed at the 
second intercostals space (the angle of Louis).  
The medial margin, if no internal mammary portal is used, should 
be at or 1 cm across the Midline. If an internal mammary field is used, 
the medial margin is 3cm across the midline ,covering the first three 
intercostals spaces. The lateral margin is usually near the mid-axillary 
line. The inferior margin is drawn 2 to 3 cm below the the 
inframammary fold . The portals used are medial and lateral tangential 
portals. 
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If only the apex of the axilla is treated (after modified radical 
mastectomy or axillary Dissection), the inferior border of the 
supraclavicular field is the first or second intercostal space . The medial 
border is 1 cm across the midline, extending upward, following the 
medial border of the sternocleidomastoid muscle to the thyrocricoid 
groove. 
The lateral border is a vertical line  at the deltoid insertion with 
the humeral head blocked as much as possible without compromising 
coverage of the high Axillary lymph nodes. This field is angled 
approximately 15 to 20 degrees laterally to spare the spinal cord . The 
portal is single AP given at D-max level or at 3 cm depth.
 
DOSE PRESCRIPTION IN PMRT 
The conventional radiotherapy dose followed for postmastectomy 
radiotherapy across many radiation oncology centres is 50 GY given in 
25 fractions over a period of 5 weeks including PA boost .Thus resulting 
a lot of burden on the existing infrastructure and manpower which are 
already stretched because of ever growing patients who are in need of 
RT, a hypofractionated Protocol i.e. reducing both the number of 
fractions and total treatment duration is being evalauted .  
For a number of years, centres in the United Kingdom and Canada 
have used more rapid Fractionation schedules for breast irradiation. This 
approach is based on the radio biologic Model that a larger dose per 
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fraction given over a shorter period of time is just as effective as the 
more traditional longer schedule . Schedules used have ranged from 40 
to 45 Gy in 15–20 fractions, administered over 19–22 days with fraction 
sizes of 2.3–2.7Gy.  
The use of a 15-fractions, instead of a 25-fractions regime, for 
instance , would save 1000 treatment sessions per 100 patients (2500 - 
1500 = 1000).  
This corresponds to an additional 66 (1000:15) patients who could 
be treated with the same number of fractions. This would result in 
substantial economic benefit as Carcinoma Breast patients represent the 
majority of patients treated in Radiotherapy departments.  
In a well-known randomized trial from Canada, Whelan et al 
reported equivalent results for a 10 year follow up (regarding local 
control, survival, and post-radiation effects) between the standard 
fractionation schedule of 50 Gy in 25 fractions and a hypofractionation 
scheme of 42.5 Gy in 16 fractions over 22 days for women with node-
negative early Ca Breast.  
The START A trial randomized 2236 patients from 17 centres 
across the UK and reported that 41.6 Gy/13 fractions or 39 Gy/13 
fractions are similar to 50 Gy/25 fractions in terms of local-regional 
tumour control and late normal tissue effects . 
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The START A trial showed that after a median follow-up of 5.1 
years, the rate of local-regional tumor relapse at 5 years was 3.6% [95% 
confidence interval (CI): 2.2%-5.1%] after 50 Gy, 3.5% (95% CI: 2.1%-
4.3%) after 41.6 Gy, and 5.2% (95% CI: 3.5%-6.9%) after 39  
Gy. The estimated absolute differences in 5-year local-regional 
relapse rates compared with 50 Gy were 0.2% (95% CI: -1.3%-2.6%) 
after 41.6 Gy and 0.9% (95% CI: -0.8%-3.7%) after 39 Gy. 
The START B trial randomized 2215 patients from 23 centres 
across the UK and reported that a RT schedule of 40 Gy/15 fractions 
offers equivalent results to the standard schedule of 50 Gy/25 fractions. 
After a median follow-up of 6.0 years, the rate of Local-regional tumour 
relapse at 5 years was 2.2% (95% CI: 1.3%-3.1%) in the 40 Gy group 
and 3.3% (95% CI: 2.2%-4.5%) in the 50 Gy group. Photographic and 
patient self assessments indicated lower rates of late adverse effects 
after 40 Gy than after 50 Gy.  
Another short RT schedule, 40 Gy in 15 fractions, has been used 
traditionally at Christie Hospital in Manchester, UK; the reported results 
of 2159 treated patients are Comparable to those reported from other 
centres, this schedule is now becoming the “standard” in the UK, 
especially after the publication of the START trials. 
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Institute of Nuclear Medicine & Oncology (INMOL) Pakistan, 
published a Randomised result of three hypofractionation protocols in 
postmastectomy carcinoma breast in terms of local control, toxicity and 
work load .A total of three hundred patients with stage T2-4, N any were 
randomized into three arms after mastectomy. All the patients were 
treated with four fields on Co60 and were randomized into three arms 
i.e. 2700 CGy in 5 fractions (one week) arm A,3500 CGy in 10 
fractions(2 weeks)arm B and 4000 CGy in 15 fractions (3 weeks) arm C 
Skin, cardiac, pulmonary and haematological toxicities and 
lymphoedema, and workload were studied. The loco regional relapses 
were 11%, 12% and 10% in arms A, B and C respectively. 26%, 24% 
and 28% patients developed metastatic disease and 17%, 18% and 20% 
died in the three arms . G3 and G4 skin toxicities were 37%, 28% and 
14%. G2 and G3 lymphedoema was 21%, 22% and 27% . Cardiac 
toxicity was 5%, 6% and 5% while pulmonary toxicity was 4%, 5% and 
5% respectively . All the differences except skin toxicity were 
statistically Insignificant . There were no cases of haematological 
depression or rib fractures all the three short protocols were equally 
effective in loco regional disease control and toxicity was also 
comparable.  
An Indian Study from January 1989 to June 1992 on 108 Ca 
Breast patients at Pt. B. D. Sharma Post Graduate Institute of Medical 
Sciences, Rohtak by A Goel, V Kaushal, et al.,,108 patients were 
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randomly divided into 2 groups (A&B), 54 patients in Group A and 54 
patients in Group B. Group A patients were given external radiotherapy . 
40 Gy in 17 fractions over 3.2 weeks and Group B patients were given 
45 Gy in 20 fractions over 4 weeks Results of treatment in Group A 
versus Group B were as follows; chest wall failure 5/50 (10%) versus 
3/54 (5.6% ), axillary lymph node failure 3/50 (6%) versus 4/ 54 (7%), 
distant metastasis 16/50 (32%) versus 15/54 (28%). Most of the patients 
in both the groups had no evidence of disease at last follow-up i.e. 26/50 
(52%) in Group A and 32/54 (59%) in Group B. There was no 
statistically significant difference in local control and efficacy of these 
two radiation schedules in post mastectomy carcinoma of the breast . 
Gary M Freedom et al four week course of radiation for Ca Breast  
using hypofractionated intensity modulated radiation therapy (IMRT) 
with an incorporated electron boost. A total of 75 pts (age > 18 yrs) 
treated with 45 Gy to the whole  breast and the lumpectomy bed 56Gy in 
20 treatments over 4 wks The treatment was feasible and is associated 
with acceptable acute skin toxicity. This may represent an alternative to 
longer 6-week standard radiotherapy 
“LIMITS OF HYPOFRACTIONATION IN BREAST RT: FAST 
This trial tested 30 Gy in 5 fractions (6 Gy/fraction) over 35 d (5 
wk) vs 28.5 Gy (5.7 Gy/fraction) over 35 d vs 50 Gy in 25 fractions over 
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35 d (control arm) No recurrences were seen after a median follow-up of 
3 years. 
Table 10: Comparision of hypofractionation schedules  
 
 
Trial Dose 
No. of 
Weeks 
%CRF 
% Good 
Excellent 
Cosmesis 
Follow-
up (Yr) 
RMH/ 
GOC 
50Gy/2Gy/25 5 12.1 47* 10act 
 39Gy/3Gy/13 5 14.8 42*  
 42.9Gy/2Gy/25 5 9.6 44*  
Canadian 50Gy/ 2Gy/25 5 6.7 70 10act 
 42.5Gy/ 
2.66Gy/16 
3.1 6.2 71  
Start-A 50Gy/2Gy/25 5 3.6 59* 5 
 41.6Gy/3.2Gy/13 5 3.5 59*  
 39Gy/3Gy/13 5 5.2 70*  
Start-B 50Gy/2Gy/5 5 3.3 57* 5 
 40Gy/2.67/15 3 2.2 64* 5 
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RADIOBIOLOGY 
The Optimization of a RT schedule for individual patients with 
regards to Total dose and number of fractions and overall time of the 
radiotherapy course keeping in thought about Tumour Control 
probability (TCP) and normal tissue Complication probability (NTCP) is 
possible. The response depends not only on dose but also on individual 
Radio sensitivity, timing, fraction size, other agents given concurrently.  
NORMAL AND TUMOUR CELLS: THERAPEUTIC RATIO 
The principle of radiotherapy is demonstrated by plotting two 
sigmoid curves. 
 
Figure 2: graph showing therapeutic ratio  
The principle of therapeutic ratio, Curve A represents the TCP, 
curve B the Probability Of Complications, the total clinical dose is 
usually delivered in 2 Gy fractions. Thus optimum choice of radiation 
dose delivery technique in the treatment of a given tumour is such that it 
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maximizes the TCP and simultaneously minimizes the NTCP for a 
typical good radiotherapy treatment, TCP ≥ 0.5 and NTCP < 0.05 
The further curve B (NTCP) is to the right of curve A (TCP) the 
easier it is to achieve the radio therapeutic goal, the larger is the 
therapeutic ratio and the less likely will it be that the treatment causes 
complications. The therapeutic ratio generally refers to the ratio of the 
TCP and NTCP at a specified level of response (usually 0.05) for normal 
tissue. 
CELL SURVIVAL CURVE 
The surviving fraction of cells, i.e., the fraction of irradiated cells 
that maintain their reproductive integrity (clonogenic cells). Several 
factors can modify the cells less radio-sensitive: 
 Removal of oxygen to create a hypoxic state.
 Use of low dose rates or multi-fractionated irradiation
 Addition of chemical radical scavengers
 Synchronization of cells in the late S phase of the cell cycle.
PROPERTIES OF CELL SURVIVAL CURVES 
 late responding tissues indicate the survival curves are more 
curved than those for early Responding tissues 
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 In early effects the ratio α/β is large; for late effects it  is small 
and  α dominates at low doses.  
 For late effects β has an influence at doses lower than for early 
responding tissues 
 The α and β components of mammalian cell killing are equal at 
the following doses:
o α/β ≈ 10 Gy for early responding tissues
o α/β ≈ 3 Gy for late responding tissues 
 
Figure 3: graph showing early vs late responding tissue in terms of 
dose and surving fraction 
 
ISOEFFECT FORMULA 
The effect of changes of dose fractionation schedule on the total 
dose required to produce a certain level of biologic effect is 
approximated by the isoeffect curves or formulas The first clinical 
isoeffect curve was produced by Strandqvist  and later modified by 
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Fowler and Stern.These observations led to the formulation of Normal 
Standard Dose (NSD) formula of Ellis 
D  ≈ N0.24 x T0.11 
Where, N = Number of dose fractions, T = Overall time.  
 
Figure 4:Isoeffect curve on effects and therapeutic potential  
 
This formula is purported to represent the effect of changing 
fractionation parameters on the tolerance of normal connective tissue, 
which are considered to impose the ultimate dose limitation for all 
radiation therapy. From the NSD concept, tolerance dose formula and 
the cumulative radiation effect (CRE) formula were derived Later, it was 
recognized that the exponents N and T used in NSD formula was not 
appropriate for all tissue types . In general, Isoeffect curves for late 
reacting normal tissues were characterized by larger exponents of N and 
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smaller components of T. This led to the modification of the formula on 
Tissue specific basis.  
Thames et al stated that curvier survival curve would be expected 
for target cells in tissues in which isoeffect dose increased more steeply 
with Decreasing dose per fraction and that this steepness could be 
quantified by the ratio α/β in case the LQ model correctly described 
target cell response  
THE LINEAR-QUADRATIC MODEL 
Is most often used in describing the cell surviving fraction S(D), 
with the assumption that there are two components to cell kill by 
radiation (linear and quadratic): 
Equation 1 
 
 
 α is a constant describing the initial slope of the cell survival 
curve 
 β is a smaller constant describing the quadratic component.  
The currently used model for describing the cell survival curve is 
the the linear quadratic model with constants α and β. The ratio α/β 
gives the dose at which the linear and quadratic Components of cell 
killing are equal. 
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Figure 5 linear quadratic model 
The LQ formalism is now almost universally used for calculating 
Radio therapeutic isoeffect (31),In summary, LQ has the fol lowing 
useful properties for predicting isoeffect useful properties for predicting 
isoeffect doses  
1) A mechanistic, biologically-based model 
2) Has sufficiently few parameters to be practical  
3) Most other mechanistic models of cell killing predict the same 
fractionation dependencies as does LQ fourth, it has well 
documented predictive properties for fractionation/dose- rate 
effects in the laboratory 
4) Well validated, experimentally and theoretically, up to about 10 
Gy / fraction, and would be reasonable for use up to about 18 Gy 
per fraction 
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RELATIVE BIOLOGICAL EFFECTIVENESS 
Relative biological effectiveness (RBE) compares the dose of 
radiation to the dose of standard radiation to produce the same 
biological effect. 
  Dose from standard radiation to produce a given biological effect 
RBE =  ---------------------------------------------------------------------------  
  Dose from test radiation to produce the same biological effect  
Equation 2 
 
The RBE varies with  
1) Type of radiation 
2) Type of cell/ tissue 
3) Biologic effect under investigation 
4) Dose rate 
5) Fractionation 
The RBE increases with the LET to reach a maximum RBE of 3–8 
depending on the level of cell kill) at LET 200 keV/m and then 
decreases because of energy overkill, an increase in the RBE in itself 
offers no therapeutic advantage unless there is a differential effect 
making the RBE for normal tissue smaller than that for the tumour, 
Increasing the relative level of tumour cell killing and the therapeutic 
ratio. 
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The isoeffect curves vary for different tissues. A biologically 
equivalent dose (BED) can be obtained using this formula  
 
Equation 3 
Use of BED to calculate equivalent doses when changing 
fractionation, comparison of equivalent regimens and determination of 
the isoeffective single dose in groups of tumours with similar kinetics 
(α/β ratio) is possible. (33)  
 
Equation 4 
n = standard number of fractions , n 1 = equivalent number of 
fractions in altered schedule, d = standard dose/fraction, d 1= desired 
dose/fraction  
/ FOR BREAST TISSUE 
Low α/β ratio for breast cancer has drawn a growing interest for 
exploring Hypofractionation for breast irradiation, Post operative 
radiotherapy (RT) is widely used to reduce local recurrence of 
carcinoma Mammary Gland. Conventionally, a dose per fraction of 1.8–
2.0 Gy in 25 fractions over 5–6 week treatment duration has been widely 
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used. Recently, it has been argued that the α/β ratio for carcinoma 
Mammary Gland may be lower than previously Considered  .  
Based on large randomized clinical trials of whole breast 
irradiation, the analysis from multiple institutions yields ratios in the 
range of 0.75–5.01 Gy 95% CL, supporting that carcinoma Mammary 
Gland has a low α/β ratio. Such a low α/β ratio suggests that 
hypofractioated radiotherapy regimens may be advantageous for 
carcinoma Mammary Gland.  
Using the low α/β ratio , selected possible fractionated regimens 
that are radio biologically equivalent to the conventional 2.0 Gy* 25 # , 
regimens were calculated and were studied in many studies with a 
standard value of 3 for delayed effects and 10 for early reactions  
Table 11: Radiobiological parameters of hypofractionated trials  
 
CONVENTIONAL FRACTIONATION 
It is the application of daily doses of 1.8 to 2 Gy and 5 fractions 
per week. Total dose depends on tumour histology, tumour size and 
Localisation, macroscopic or microscopic disease. 
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HYPOFRACTIONATION 
Hypofractionation means the use of a reduced number of 
fractions, or a larger dose Per Fraction, if the dose per fraction is 
increased above the reference value of 2 Gy, then the total dose  (for an 
isoeffect) must be reduced as indicated in this graph . 
 
Figure 6:comparision based on α/β 
Compared with a reference treatment using 2 Gy per fraction, the 
diagram shows how the total dose must be changed in order to maintain 
a constant level of effect when dose per fraction is modified. Full lines 
are for low α/β ratios (as in late-responding normal tissues), and broken 
lines are for early-responding normal tissues or for most tumours  
For tumours with lower α/β values compared with the 
Surrounding normal tissues, hypofractionation may be a viable option to 
improve the therapeutic ratio of Radiotherapy, particularly as 
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hypofractionation may also be a convenient way to accelerate the 
treatment, thereby counteracting repopulation  
Most tumors are actively proliferating and rapidly responding, and 
their fractionation response is similar to that of acute-responding normal 
tissues, although there are exceptions. one of the main principles of 
radiobiology is that the late effects of normal tissues are strongly 
dependent on the size of dose per fraction, so that the higher the dose 
per fraction the greater the susceptibility of healthy tissues to radiation. 
This is known as “fractionation sensitivity  
Fractionation sensitivity of tissues is quantified, in terms of linear 
quadratic (LQ) isoeffect formulation, by the α/β ratio the higher the 
sensitivity to the size of dose per fraction, the lower the α/β ratio is 
Additionally the only drawback of applying a Hypofractionation Scheme 
using an α/ß ratio of > 4 Gy was to expect more late effects. 
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Aims And Objectives  
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AIMS AND OBJECTIVES 
PRIMARY OBJECTIVE 
To assess the loco regional tumour control between conventional 
fractionation radiotherapy and hypofractionation radiotherapy in post 
operative carcinoma breast patients. 
SECONDARY OBJECTIVE 
To evaluate the toxicities and quality of life and compliance of 
the patients. 
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Materials And 
Methods 
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MATERIALS AND METHODS 
RECRUITMENT 
All The patients in this study were registered in the Department of 
Radiotherapy,BIRO,Rajiv Gandhi Government General Hospital.  
Assessment was done for the requirement criteria of the study 
The study period was for the period of July 2017-June 2018 
60 patients were recruited,with 30 each in conventional arm 
<ARM A> and 30 each in hypofractionated arm<ARM B> 
DATA COLLECTION 
Personal and clinical data of the patients were collected such as –
Name, Age, Sex, Address, Occupation, Presenting symptoms, Past 
medical / surgical history, Co-Morbidities, family history, General 
examination,Local examination. 
Their treatment plan was completing chemotherapy,surgery and 
then radiotherapy <i.e. Post Mastectomy Radiation Therapy> 
RANDOMIZATION OF THE PATIENTS 
60 patients were recruited and then divided 30 into each arm,  
hypofractionated and conventional arm. This selection was randomized 
which was done through a software IBM SPSS 19.  
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INCLUSION CRITERIA 
 Histologically proven malignant tumour of the breast  
 Tumour staging-T2/T3/T4,Nodal Staging-N0/N1/N2/N, Metastasis 
- MO STAGING 
 Underwent Modified Radical Mastectomy 
EXCLUSION CRITERIA 
 Metastatic breast cancer patients 
 History of non malignant disorder <severe cardiac or severe 
pulmonary disease> 
 Psychiatric illness 
 Co mordibities – uncontrolled diabetes/uncontrolled hypertension 
LIST OF INVESTIGATIONS DONE BEFORE THE STUDY 
 Lab Investigations 
 Metastatic survey 
 Pulmonary function test 
 ECHO 
 ECG 
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TREATMENT PLAN 
2D planning 
External beam radiotherapy-Post Mastectomy Radiotherapy 
Chest wall-2 tangential fields 
Drainage - Single anterior field 
Posterior axillary boost 
Machine: Cobalt 60 <Theratron Phoenix 60 > 
Position: Supine with shoulder flexed at 90degree and elbow 
flexed at 90 degree 
Shielding: Humerus and trachea shielding 
DOSE 
Table 12:Conventional and Hypofractionation arm schedules  
 Arm A Arm B 
Dose per Fraction 2Gy 2.67Gy 
No. Of Fractions 25# 15# 
Total Dose 50Gy 40Gy 
Duration 5 weeks 3 weeks 
Arm A- conventional arm , 2Gy/25#/50Gy 
Arm B- Hypofractionated arm , 2.67Gy/15#/40Gy 
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Field borders and isocentres was marked with permanent marker 
for each patient,based on anatomical landmarks.Patient was positioned 
and instructed to maintain the same position till treatment is over.The 
position for all patients was supine with the arm abducted at 90degree 
and elbow flexed at 90 degree and the head turned to the opposite side. 
CHEST WALL FIELD 
Upper border- second intercostal space 
Lower border-2cm below the inframammary fold 
Medial border – midline 
Lateral border- mid axillary line 
Two tangential portals were used to treat the chest wall  
While marking the field borders,the scar and the drain site was 
also covered in the field. 
Chest wall contour was taken and drawn in the paper and target 
volume was marked. 
Chest wall thickness was determined using ultrasound technique 
and the central lung distance was determined. 
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Figure 7:Field borders 
ASSESSMENT 
Before starting on radiotherapy 
 Skin assessment 
 Lymph edema 
 PFT 
 ECHO 
At regular intervals, that is weekly, monthly, 3 and 6 monthly 
periods –assessment of the following was done 
 Skin toxicity 
 Lymph edema 
 PFT 
 ECHO 
 Metastatic survey 
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Table 13: ECOG grading 
Grade ECOG Performance Status 
0 Fully active, able to carry on all pre-disease performance 
without restriction 
1 Restricted in physically strenuous activity but ambulatory and 
able to carry out work of a light or sedentary nature, e.g., light 
house work, office work 
2 Ambulatory and capable of all selfcare but unable to carry out 
any work activities; up and about more than 50% of waking 
hours 
3 Capable of only limited selfcare; confined to bed or chair 
more than 50% of waking hours 
4 Completely disabled; cannot carry on any selfcare; totally 
confined to bed or chair 
5 Dead 
 
Table 14:Skin toxicity grading(CTCAEv5) 
Grade 1 Faint erythema or dry desquamation 
Grade 2 
Moderate to brisk erythema; patchy moist desquamation, 
mostly confined to skin folds and creases; moderate edema 
Grade 3 
Moist desquamation in areas other than skin folds and creases; 
bleeding induced by minor trauma or abrasion 
Grade 4 
Life-threatening consequences; skin necrosis or ulceration of 
full thickness dermis; spontaneous bleeding from involved 
site; skin graft indicated 
Grade 5 Death 
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Table 15:Grading of Radiation pneumonitis (CTCAEv5) 
Grade 1 Asymptomatic; clinical or diagnostic observations only;  
intervention not indicated  
Grade 2 Symptomatic; medical intervention indicated;  
limiting instrumental ADL  
Grade 3 Severe symptoms; limiting self care ADL; oxygen indicated  
Grade 4 Life-threatening respiratory compromise; urgent intervention  
indicated (e.g., tracheotomy or intubation)  
Grade 5 Death  
 
Table 16:Lymphedema (CTCAEv5) 
Grade 1 Trace thickening or faint discoloration  
Grade 2 
Marked discoloration; leathery skin texture; papillary formation;  
limiting instrumental ADL  
Grade 3 Severe symptoms; limiting self care ADL  
PULMONARY FUNCTION TEST 
PFT was measured and  FEV1 and FVC was recorded before 
starting RT and after 2 and 6 months 
X-ray Chest  was also done 
Any abnormalities detected in the PFT and those patients were 
excluded from the study. 
 
 57 
CARDIAC TOXICITY 
Baseline ECG 
Baseline ECHO 
Any abnormalities detected and those patients were excluded from 
the study 
QUALITY OF LIFE 
EORTC QLQ - BR23 
Patients sometimes report that they have the following symptoms 
or problems. Please indicate the extent to which you have experienced 
these symptoms or problems during the past week.  
1-Not at all,  2-A little, 3-Quite a bit, 4-Very much 
  1 2 3 4 
31. Did you have a dry mouth?      
32. Did food and drink taste different than usual?      
33. Were your eyes painful, irritated or watery?      
34. Have you lost any hair?      
35. Answer this question only if you had any hair loss: 
Were you upset by the loss of your hair?  
    
36. Did you feel ill or unwell?      
37. Did you have hot flushes?      
38. Did you have headaches?      
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  1 2 3 4 
39. Have you felt physically less attractive as a result of 
your disease or treatment?  
    
40. Have you been feeling less feminine as a result of your 
disease or treatment?  
    
41. Did you find it difficult to look at yourself naked?      
42. Have you been dissatisfied with your body?      
43. Were you worried about your health in the future?      
44. To what extent were you interested in sex?      
45. To what extent were you sexually active? (with or 
without intercourse)  
    
46. Answer this question only if you have been sexually 
active: To what extent was sex enjoyable for you?  
    
47. Did you have any pain in your arm or shoulder?      
48. Did you have a swollen arm or hand?      
49. Was it difficult to raise your arm or to move it 
sideways?  
    
50. Have you had any pain in the area of your affected 
breast?  
    
51. Was the area of your affected breast swollen?      
52. Was the area of your affected breast oversensitive?      
53. Have you had skin problems on or in the area of your 
affected breast (e.g., itchy, dry, flaky)?  
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ENGLISH 
EORTC QLQ-C30  
  1 2 3 4 
1. Do you have any trouble doing strenuous activities, 
like carrying a heavy shopping bag or a suitcase? 1 
2 3 4 
    
2. Do you have any trouble taking a long walk? 1 2 3 
4 
    
3. Do you have any trouble taking a short walk 
outside of the house? 1 2 3 4 
    
4. Do you need to stay in bed or a chair during the 
day? 1 2 3 4 
    
5. Do you need help with eating, dressing, washing 
yourself or using the toilet? 1 2 3 4 
    
6. Were you limited in doing either your work or 
other daily activities? 1 2 3 4 
    
7. Were you limited in pursuing your hobbies or other 
leisure time activities? 1 2 3 4 
    
8. Were you short of breath? 1 2 3 4     
9. Have you had pain? 1 2 3 4     
10. Did you need to rest? 1 2 3 4     
11. Have you had trouble sleeping? 1 2 3 4     
12. Have you felt weak? 1 2 3 4     
13. Have you lacked appetite? 1 2 3 4     
14. Have you felt nauseated? 1 2 3 4     
15. Have you vomited? 1 2 3 4     
16. Have you been constipated? 1 2 3 4     
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  1 2 3 4 
17. Have you had diarrhea? 1 2 3 4     
18. Were you tired? 1 2 3 4     
19. Did pain interfere with your daily activities? 1 2 3 
4 
    
20. Have you had difficulty in concentrating on things, 
like reading a newspaper or watching television? 1 
2 3 4 
    
21. Did you feel tense? 1 2 3 4     
22. Did you worry? 1 2 3 4     
23. Did you feel irritable? 1 2 3 4     
24. Did you feel depressed? 1 2 3 4     
25. Have you had difficulty remembering things? 1 2 3 
4 
    
26. Has your physical condition or medical treatment 
interfered with your family life? 1 2 3 4 
    
27. Has your physical condition or medical treatment 
interfered with your social activities? 1 2 3 4 
    
28. Has your physical condition or medical treatment 
caused you financial difficulties? 1 2 3 4 
    
For the following questions please circle the number between 1 and 7 
that best applies to you 
29. How would you rate your overall health during the past week? 1 2 3 
4 5 6 7 
Very poor Excellent 
30. How would you rate your overall quality of life during the past 
week? 1 2 3 4 5 6 7 
Very poor Excellent 
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RESULTS 
AGE DISTRIBUTION PROFILE 
Table 17:age distribution profile 
 arm A arm B 
41-50 1 1 
51-60 18 21 
61-70 11 8 
 
In the 41-50 years age group,1 patient for each arm was recruited 
and this being the least number of patients group.In the 51-60 years age 
group,18 patients were in arm A and 21 in arm B,thus majority of the 
patients were in this group.The rest of the patients were in the age group 
of 61-70 years age group, with 11 in arm A and 8 in arm B.  
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BASED ON THE SIDE,WHETHER LEFT OR RIGHT  
Table 18: Right or left sided presentation 
 ARM A ARM B 
T2N1MO 1 1 
T2N2MO 0 0 
T2N3MO 0 0 
T3NOMO 0 0 
T3N1MO 3 2 
T3N2MO 0 0 
T3N3MO 0 0 
T4N0MO 2 3 
T4N1MO 9 11 
T4N2MO 7 6 
T4N3MO 8 7 
 
In arm A, 16 patients were left breast cancer patients and 14 
patients were right breast cancer patients.  
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STAGING DISTRIBUTION 
Table 19:Stage distribution 
 ARM A ARM B 
T2N1MO 1 1 
T2N2MO 0 0 
T2N3MO 0 0 
T3NOMO 0 0 
T3N1MO 3 2 
T3N2MO 0 0 
T3N3MO 0 0 
T4N0MO 2 3 
T4N1MO 9 11 
T4N2MO 7 6 
T4N3MO 8 7 
 
Based on AJCC,cases were staged and the distribution was 
analysed.Majority of the cases were from T4N1M0,which accounts 20 cases,9 
cases from arm A and 11 cases from arm B.T4N3M0 had 15 cases with 8 from 
arm A  and 7 from arm B.While,T4N2M0 had 13 cases with 7 from arm A and 
6 from arm B.While T4N0M0 had 5 cases,where 2 cases from arm A and 3 
cases from arm B.T3N1M0 had 5 cases,3 cases from arm A and 2 cases from 
arm B.Whereas T2N1M0 had the least number of cases with 1 from each 
arm,totally 2 cases. 
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GRADING OF SKIN TOXICITIES 
Table 20:Skin toxicities grading 
SKIN ARM A ARM B 
GRADE 1 19 2 
GRADE 2 10 0 
GRADE 3 1 0 
GRADE 4 0 0 
GRADE 5 0 0 
 
A wide variety of symptoms appear after radiation.This skin 
toxicity affects the quality of life and cosmesis of the patient.  
Skin toxicities was reported,with grade 1 skin toxicity in Arm A 
reported in 19 patients and Arm B reported 2 patients.Grade 2 skin 
toxicity was reported in Arm A for 10 patients and Arm B had nil 
cases.For grade 3 skin toxicity,only one case was reported and that too 
in arm A. 
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RADIATION PNEUMONITIS 
Table 21:Radiation pneumonitis 
PNEUMONITIS ARM A ARM B 
GRADE 1 4 4 
GRADE 2 0 0 
GRADE 3 0 0 
GRADE 4 0 0 
GRADE 5 0 0 
 
Generally,symptomatic pneumonitis is infrequent.The risk for 
developing  this toxicity is correlated to the radiation of lung volume.  
Radiation pneumonitis was reported in totally 8 cases,with 4 cases 
in arm A and 4 cases in arm B.Thus these cases were graded Grade 1 
under the CTCAE version 5.0. 
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PULMONARY FUNCTION TEST 
Table 22:Pulmonary function test 
PFT ARM A ARM B 
DECREASE 0 0 
NO CHANGE 30 30 
INCREASE 0 0 
 
 
Pulmonary function changes are usually reversible,if any occurs. 
Pulmonary function test was analysed and there was no change in PFT 
in both the arms. 
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CARDIAC STATUS BASED ON LVEF 
Table 23:Cardiac status 
LVEF ARM A ARM B 
NO CHANGE 30 30 
DECREASE 0 0 
 
This cardiac function whether it is affected by radiation or not is a 
most evaluated topic currently.  
All the 60 cases both in arm A and arm B had no changes in the 
Left ventricular ejection fraction. 
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LYMPHEDEMA GRADING 
Table 24:lymphedema  
LYMPHEDEMA ARM A ARM B 
GRADE 1 30 30 
GRADE 2 0 0 
GRADE 3 0 0 
GRADE 4 0 0 
 
Lymphedema is a common complication in breast cancer 
patients.It occurs after surgery and radiation therapy and sometimes 
manifest as recurrence. 
All the 60 patients in both the arms had grade 1 lymphedema. 
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RIB FRACTURE 
Table 25:Rib fracture 
RIB FRACTURE ARM A ARM B 
YES 0 0 
NO 30 30 
 
There was no cases of rib fractures among all the 60 cases.  
 72 
COMPLIANCE ANALYSIS 
Table 26:Compliance 
COMPLIANCE ARM A ARM B 
PREFERENCE 4 56 
COMPLETED 28 30 
 
An analysis of compliance was done and the patients was asked 
whether they preferred 5 weeks treatment which is arm A or arm B 
which is of 3 weeks. 
Many patients ,that is around 56 patients preferred the 3 weeks 
treatment duration that is arm B while only 4 preferred 5 weeks 
treatment duration that is arm A. 
When it comes to completion of treatment,arm A had 28 patients 
successfully completing the 5 weeks schedule and while arm B had all 
the 30 patients completing the 3 weeks treatment.  
So majority of them preferred 3 weeks duration of treatment and 
when it comes to completion of treatment ,arm B successfully had 100% 
compliance. 
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DISCUSSION  
In the past century,keeping the palliative idea in mind,different 
hypofractionation schedules were studied as Treatment of Carcinoma 
Breast, but this lead to a lot of challenges and also the severity of late 
effects increased which led to constant scrutiny of these protocols.  
Shorter schedules based on radiobiological models offer the loca l 
control to standard radiation therapy by giving larger doses per fraction 
in shorter time frame. 
Thus hypofractionated Radiotherapy as adjuvant and accelerated 
Radiotherapy schedules with adjuvant role  have been evaluated in phase 
III trials.  
The linear-quadratic model is used to calculate the biologically 
equivalent dose taking  account a larger dose per fraction over a shorter 
time a α/ß ratio study from several studies and research which 
experimented from cell culture lines have suggested that certain  
carcinomas including breast Carcinomas have low α/β ratios supporting 
the idea that hypofractionation is likely to be Effective.  
This study is based on many studies in many cancer centres with 
special mention of  Institute of Nuclear Medicine & Oncology ( INMOL) 
study whereas they were using a three arm hypofractionated protocols in 
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Postmastectomy carcinoma breast in terms of local control, toxicity and 
work load. 
This hypofractionated protocol is being used in IMRT and in 
younger age groups ,thus tackling the time window for treatment since 
IMRT is a time draining process and this hypofractionation might 
supplement. 
The advantages of a hypofractionated Post Mastectomy Radiation 
Therapy are good option for  patients and the institute in matters of 
economic cost,time spent and manpower. This also will  help the family 
sustain their quality of life without affecting much of their daily 
routines. 
Radiation pneumonitis, a well known toxicity of chest wall RT,is 
usually asymptomatic. Lingos et al reported radiation pneumonitis in 1% 
of patients post op post RT and was observed to be 9% when three fields 
were used with concurrent chemo was administered.  
Plataniotis GA et al evaluated radiation pneumonitis in 
hypofractionation setting (42.5 Gy / 16 Fr) by HRCT in early Ca Breast 
patients, and reported minimal and minor effects on the underlying lung 
parenchyma. 
In the chest wall some portion of the heart has to be included in 
the tangential portals. Another important factor in this regard is the 
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administration of anthracyclines which again cause cardio toxicity, 
which is always a reason for concern. Different techniques have been 
used in different trials to assess the cardio toxicity of Chest wall 
radiotherapy.  
In the present study 2D echocardiography and ecg was used as a 
standard to observe effects detrimental and indicate cardiac toxicity. 
Radiotherapy following mastectomy has been seen to increase the risk of 
death due to cardiac causes after 10-15 years post RT.  
The Swedish cancer registry data showed an increased risk of 
death due to myocardial infarction for patients with left sided lesions 
(RR 1.09). In the Oslo and Stockholm trials, the retrospective analysis 
showed that increase in non Ca Breast deaths was attributed to cardiac 
mortality. No increase was seen in right sided Ca Breast. Gustavsson et 
al reported no cardiac deaths. 
however cardiac toxicities are a late manifestation and long term 
follow up is required .  
Lymphoedema is an established complication of both axillary 
lymph node dissection (ALND) and axillary radiotherapy.  
Chua B, etal., reported 9.5% arm edema with axillary dissection, 
6.1% with radiation and 31% when both were combined.Thus insignificant 
difference between the hypofractionated and conventional arms. 
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Erickson VS et al reported 26% lymphedoema after Ca Breast 
treatment. Petrek JA in seven selected reports showed lymphedoema in 
6-30%. At Memorial Sloan Kettering cancer centre the experience from 
1977 to 1979, lymphedoema was seen in 31%. Powel SN,etal., reported 
that axillary radiotherapy doubles the figures of lymphedoema against 
axillary surgery alone.  
Compliance plays a role in clinical outcome.Carcinoma Breast has 
a treatment role which is multimodality ,so a break in treatment or delay 
in treatment might lead radiobiologically to further growth of the 
tumour. 
Compliance becomes a major problem for the patients since daily 
reporting for radiotherapy and loss of disability adjusted life years 
which increases their burden psychologically,emotionally and 
physically. Hadji et al. stated therapy-related, patient-related, and socio-
economic factors as important reasons for non-compliance. 
Quality of life is important for patients since it affects their 
routine day to day activities and if affected may create a hindrance to 
treatment.Many patients were not willing to sacrifice their quality of life 
for the purpose of treatment and many studies prove the same and give 
quality of life an upper hand in those patients  
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CONCLUSION 
Based on the study,results and its analysis, we concluded that 
there was no significant difference in loco regional control,acute 
toxicities and patients were more in favour for hypofractionated protocol 
which is supported by the compliance and quality of life 
analysis.Further more followup is needed to assess the long term effects 
of this hypofractionation protocol. 
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INFORMATION TO PARTICIPANTS 
Title: BENEFITS OF HYPOFRACTIONATION IN POST 
OPERATIVE BREAST CANCER PATIENTS 
Name of Participant: 
Name of the Principal (co–investigator): Dr.S.N.Jagadesh Kumar 
Name of the institution: Department of radiotherapy, RGGGH, MMC. 
You are invited to take part in this research/ study/procedures/tests. 
The information in this document is meant to help you decide whether or 
not to take part. Please feel free to ask if you have any queries or 
concerns. 
What is the purpose of research? 
 A large number of breast cancer cases are in the rise and now it is 
the most common cancer diagnosed among females.  
 This affects their quality of  life,economic burden and workload 
on the radiotherapy machines. 
 A hypofractionation schedule is preferred for. The benefit of an 
increased tumor cell kill because of the large fraction size ,from 
radiobiological point of view 
 Radiotherapy will be delivered by telecobalt machine 
 Arm A- The radiation dose was 50 Gy in 25 fractions of 2 Gy per 
fraction, given 5 times a week for 5 weeks.  
 Arm B- The standard palliative radiation dose 40 Gy in 15 
fractions of  2.67Gy, given 5 times a week for 3 weeks.  
 To test the benefits of hypofractionationed versus conventional 
radiotherapy schedule 
 We have obtained permission from the Institutional Ethics 
Committee. 
The study design 
Double arm prospective study 
Study Procedures 
The study involves evaluation of  Benefits of Hypofractionation in 
post operative breast cancer patients.In addition, if you notice any 
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physical or mental change(s), you must contact the persons listed at the 
end of the document. 
You may have to come to the hospital (study site) for examination 
and investigations apart from your scheduled visits, if required. 
Possible benefits to other people 
The results of the research may provide benefits to the society in 
terms of advancement of medical knowledge and/or therapeutic benefit 
to future patients. 
Confidentiality of the information obtained from you 
You have the right to confidentiality regarding the privacy of your 
medical information (personal details, results of physical examinations, 
investigations, and your medical history). By signing this document, you 
will be allowing the research team investigators, other study personnel, 
sponsors, Institutional Ethics Committee and any person or agency 
required by law like the Drug Controller General of India to view your 
data, if required. 
The information from this study, if published in scientific journals 
or presented at scientific meetings, will not reveal your identity.  
How will your decision to not participate in the study affect you? 
Your decision not to participate in this research study will not 
affect your medical care or your relationship with the investigator or the 
institution. You will be taken care of and you will not lose any benefits 
to which you are entitled. 
Can you decide to stop participating in the study once you start?  
The participation in this research is purely voluntary and you have 
the right to withdraw from this study at any time during the course of 
the study without giving any reasons. However, it is advisable that you 
talk to the research team prior to stopping the treatment/discontinuing of 
procedures etc. 
 
Signature of Investigator    Signature of Participant 
Date        Date 
 
 
 12 
INFORMED CONSENT FORM 
Title: BENEFITS OF HYPOFRACTIONATION IN POST 
OPERATIVE BREAST CANCER PATIENTS 
Name of Participant: 
Name of the Principal (co–investigator): Dr.S.N.Jagadesh Kumar 
Name of the institution: Department of radiotherapy, RGGGH, MMC. 
_____________________________ have read the information in 
this form (or it has been read to me). I was free to ask any questions and 
they have been answered. I am over 18 years of age and, exercising my 
free power of choice, hereby give my consent to be included as a 
participant in”: BENEFITS OF HYPOFRACTIONATION IN POST 
OPERATIVE BREAST CANCER PATIENTS”. 
1. I have read and understood this consent form and the 
information provided to me. 
2. I have had the consent document explained to me.  
3. I have been explained about the nature of the study.  
4. I have been explained about my rights and responsibilities by 
the investigator. 
5. I have been informed the investigator of all the treatments I am 
taking or have taken in the past 12 months including any native 
(alternative) treatment. 
6. I have been advised about the risks associated with my 
participation in this study* 
7. I agree to cooperate with the investigator and I will inform 
him/her immediately if I suffer unusual symptoms. 
8. I have not participated in any research study within the past 
12month(s). * 
9. I agree to undergo complete blood count, renal and liver 
function test, chest x ray, CT scan   of the head and neck  
10. I am aware of the fact that I can opt out of the study at any 
time without having to give any reason and this will not affect my future 
treatment in this hospital. * 
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11. I am also aware that the investigator may terminate my 
participation in the study at any time, for any reason, without my 
consent. * 
12. I hereby give permission to the investigators to release the 
information obtained from me as result of participation in this study to 
the sponsors, regulatory authorities, Govt. agencies, and IEC. I 
understand that they are publicly presented. 
13. I have understood that my identity will be kept confidential if 
my data are publicly presented 
14. I have had my questions answered to my satisfaction.  
15. I have decided to be in the research study.  
I am aware that if I have any question during this study, I should 
contact the investigator. By signing this consent form I attest that the 
information given in this document has been clearly explained to me and 
understood by me, I will be given a copy of this consent document  
 
Name and signature / thumb impression of the participant (or legal 
representative if participant incompetent)  
 
Name ________________ Signature_____________ Date____________  
Name and Signature of impartial witness (required for illiterate 
patients): 
Name ________________ Signature_____________ Date____________ 
Address and contact number of the impartial witness:  
 
Name and Signature of the investigator or his representative obtaining 
consent 
Name ________________ Signature_____________ Date____________  
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